Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.62 |
| ▸ | NPC1 | O15118 | 2/20 | 0.62 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | NAMPT | P43490 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | KIF11 | P52732 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | RAD52 | P43351 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.46 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.46 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29793056 | 0.85 | KIF11 (0.60) | RAB9ANPC1ALDH1A1MAPTLMNA | |
| SCHEMBL1368828 | 0.85 | KIF11 (0.60) | RAB9ANPC1ALDH1A1MAPTLMNA | |
| SCHEMBL29845262 | 0.83 | KMT2A (0.61) | RAB9ANPC1NAMPTALDH1A1MAPT | |
| Ethane SCHEMBL18228141 | 0.83 | ADRA2A (0.55) | RAB9ANPC1ALDH1A1MAPTLMNA | |
| SCHEMBL4591751 | 0.83 | KMT2A (0.61) | RAB9ANPC1NAMPTALDH1A1MAPT | |
| SCHEMBL20194707 | 0.81 | KIF11 (0.53) | RAB9ANPC1HPGDALDH1A1MAPT | |
| SCHEMBL1931380 | 0.81 | NPSR1 (0.60) | RAB9ANPC1HPGDALDH1A1MAPT | |
| SCHEMBL968252 | 0.80 | CYP11B1 (0.56) | RAB9ANPC1POLBMAPTLMNA | |
| SCHEMBL4813904 | 0.80 | RAD52 (0.61) | RAB9ANPC1ALDH1A1POLBMAPT | |
| SCHEMBL11875326 | 0.80 | MAPT (0.55) | RAB9ANPC1HPGDALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3782986-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2021-02-24 | — | — | EP | disclosed |
| CN-108373416-B | Method for synthesizing diarylamine by photo/nickel concerted catalysis | 陕西师范大学 | 2020-11-17 | — | — | CN | disclosed |
| US-20140011998-A1 | DERIVATIVES OF 1-AMINO-2-CYCLOPROPYLETHYLBORONIC ACID | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-01-09 | — | — | US | disclosed |
| US-8404683-B2 | Inhibitors of the interaction between MDM2 and P53 | JANSSEN PHARMACEUTICAL N.V. (BE) | 2013-03-26 | — | — | US | disclosed |
| US-8148535-B2 | Potassium channel inhibitors | MERCK SHARP & DOHME CORP. (US) | 2012-04-03 | — | — | US | disclosed |
| US-7871982-B2 | Lincomycin derivatives and antimicrobial agents comprising the same as active ingredient | MEIJI SEIKA KAISHA, LTD. (JP) | 2011-01-18 | — | — | US | disclosed |
| US-20090233897-A1 | Potassium Channel Inhibitors | MERCK SHARP & DOHME CORP. | 2009-09-17 | — | — | US | disclosed |
| US-20090156512-A1 | potent activity against resistant pneumococci | MEIJI SEIKA KAISHA, LTD. (JP) | 2009-06-18 | — | — | US | disclosed |
| WO-2005044270-A1 | OXADIAZOLOPYRAZINE DERIVATIVES AS PHARMACEUTICALLY ACTIVE COMPOUNDS | 4SC AG (DE) | 2005-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140011998-A1 | DERIVATIVES OF 1-AMINO-2-CYCLOPROPYLETHYLBORONIC ACID | PSMB6, PSMB5, PSMB1 | RAB9A 692/4885NPC1 518/4885HPGD 3443/4885 |
| US-20090156512-A1 | potent activity against resistant pneumococci | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NAT1, NPM1 | RAB9A 377/4885NPC1 50/4885HPGD 2051/4885 |
| US-20090233897-A1 | Potassium Channel Inhibitors | KCNJ2, KCNQ2, KCNH2 | RAB9A 2246/4885NPC1 660/4885HPGD 3730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.